预约演示
更新于：2026-02-01
Indacaterol Maleate
马来酸茚达特罗
更新于：2026-02-01
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 欧盟 (2009-11-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H32N2O7 |
InChIKeyIREJFXIHXRZFER-PCBAQXHCSA-N |
CAS号753498-25-8 |
关联
109
项与 马来酸茚达特罗 相关的临床试验CTIS2024-514725-38-00
A randomized, single dose, cross-over, replicated, open-label bioequivalence study comparing indacaterol/glycopyrronium (85/43mcg inhalation powder hard capsules) (PG341 [Celon Pharma] vs Ultibro Breezhaler [Novartis])
ChiCTR2300079273
Effect of Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose triple formulation on pulmonary function, symptoms and inflammation control in patients with asthma complicated with COPD
CTRI/2023/09/057963
Prospective, open label, multicentre, single arm, Phase IV post marketing study for evaluation of safety and effectiveness of Indacaterol/Glycopyrronium/Mometasone (FDC) DPI in asthmatic patients - NIL
100 项与 马来酸茚达特罗 相关的临床结果
登录后查看更多信息
100 项与 马来酸茚达特罗 相关的转化医学
登录后查看更多信息
100 项与 马来酸茚达特罗 相关的专利（医药）
登录后查看更多信息
2,244
项与 马来酸茚达特罗 相关的文献（医药）2026-12-31ANNALS OF MEDICINE
Clinical impact of disease stability on exacerbation and mortality in COPD: a retrospective cohort study
Article
作者: Lee, Hyun Woo ; Kim, Sang Hyuk ; Lee, Jung-Kyu ; Min, Kyung Hoon ; Kim, Deog Kyeom
BACKGROUND:
Disease stability is an achievable goal in chronic obstructive pulmonary disease (COPD) management. However, the clinical implications of disease stability in patients with COPD remain unclear.
METHODS:
We conducted a single-center retrospective cohort study using the electronic medical records of treated patients with symptomatic COPD. Patients who had newly initiated inhaler therapy with long-acting β2-agonist/long-acting muscarinic antagonist (LABA/LAMA) or inhaled corticosteroid/LABA/LAMA combinations were included. Disease stability was defined over a one-year assessment period as meeting all of the following criteria: (1) symptom stability; (2) no moderate or severe exacerbations; and (3) no rapid decline in lung function. The outcomes included acute exacerbations and all-cause mortality.
RESULTS:
Of the 725 screened patients, 405 were eligible for inclusion in the study. Among them, 158 (39.0%) achieved disease stability. The proportions of patients who met each criterion were 70.4% for symptom stability, 63.7% for no exacerbations, and 71.4% for a non-rapid lung function decline. Only 5.9% met none of these criteria. During the follow up duration of median 62 (interquartile ranges, 30-90) months, disease stability was significantly associated with a reduced risk of moderate-to-severe (adjusted hazard ratio [aHR] 0.521, 95% confidence interval [CI] 0.392-0.692) and severe (aHR 0.393, 95% CI 0.279-0.553) exacerbations after adjusting for confounders. It was also associated with a decreased mortality risk (aHR 0.345, 95% CI 0.135-0.883).
CONCLUSION:
Disease stability was associated with a lower risk of exacerbation and mortality, suggesting its potential role as a treatment target and outcome measure for COPD.
2026-03-01HEART & LUNG
Medication management, health outcomes, and economic burden of severe asthma stratified by asthma control levels
Article
作者: Wu, Jing ; He, Xiaoning ; Zhang, Ke
BACKGROUND:
Severe asthma-a critical subset of asthma-is known for escalating the risk of asthma-related symptoms. However, current research on the management and burden of severe asthma in developing countries remains limited, especially in China, constraining evidence-based policymaking.
OBJECTIVES:
This study aims to evaluate the medication management, health outcomes, and economic burden of severe asthma across different control levels in China.
METHODS:
We analyzed routinely collected data on nearly 1.7 million subjects from Tianjin, China. Severe asthma was identified based on specific medication use patterns. Patients were stratified as uncontrolled, suboptimally controlled or controlled according to the inpatient admission, short-term systemic corticosteroid use and short-acting inhaled beta₂-agonist use. Over a one-year follow-up period, the medication management, health outcomes, and economic burden were assessed.
RESULTS:
A total of 2418 patients with severe asthma were identified. Inhaled corticosteroids/long-acting beta2-agonist (ICS/LABA) was the most commonly used controller medication (93.51 %), while patients with poorer control spent more on additional controller medications and Chinese herbal medicines. Oral corticosteroids (OCS) were less used (10.75 %), but the mean daily dosage of OCS among OCS users was as high as 15.68 mg-1.6 times the recommended dosage in Chinese guidelines. Only 17.78 % of patients with severe asthma demonstrated good adherence (defined as proportion of days covered ≥ 0.8) to asthma control treatment. Patients with uncontrolled asthma showed a significantly high proportion of exacerbations (51.42 %) and incurred higher asthma-related medical cost than suboptimally controlled and controlled patients (CNY 8506.83 vs. 3559.35 vs. 2105.70, p = 0.000).
CONCLUSION:
Patients with severe asthma exhibit poor treatment adherence, low OCS usage rates but excessively high doses among users, pursuit of alternative therapies, and a high economic burden in Tianjin, China. These findings underscore the urgent need to improve severe asthma management, particularly for those with uncontrolled asthma.
2026-02-01JOURNAL OF ASTHMA
Asthma control and its predictors: a clinic-based study of demographic, therapeutic, and environmental associations
Article
作者: Sine, Hasnaa ; Achbani, Abderrahmane ; Rida, Jamila ; Bouchriti, Youssef ; Serhane, Hind
BACKGROUND:
Asthma is a chronic disease whose control varies depending on multiple clinico-epidemiological factors. In Morocco, few studies have analyzed these determinants in specific regional contexts, such as Agadir.
OBJECTIVE:
This study aimed to assess asthma control and identify associated factors among adult and adolescent patients followed in allergy consultations in the Agadir region.
METHODS:
A retrospective analysis was conducted on 58 patients aged 12 years and older, diagnosed with persistent asthma and followed between March 2022 and December 2024. Asthma control was assessed using the Asthma Control Test (ACT), classifying patients into two groups: controlled (ACT score 20-25) and uncontrolled (score ≤19). The variables studied included demographic, socioeconomic, clinical, therapeutic, and environmental factors. Descriptive and inferential statistical analyses (Fisher's tests, logistic and linear regressions) were performed.
RESULTS:
Among participants, 77.6% (n = 45) had controlled asthma, while 22.4% (n = 13) had uncontrolled asthma. No significant association was found with sex (p = 0.448) or ICS + LABA treatment (p = 0.283). Patients hospitalized for asthma had poorer control (64.7% vs. 82.9%, p = 0.123). Age influenced control, with 100% of 12-19-year-olds achieving control compared to 60% of those ≥60 years (p = 0.045). A secondary education level was associated with better control (AOR = 4.02, p = 0.070), while cold exposure significantly increased hospitalization risk (OR = 19.156, p = 0.019).
CONCLUSIONS:
Asthma control in this population was mostly good but influenced by age, education, and cold exposure. These findings highlight the importance of targeting modifiable factors, such as therapeutic education and protection against environmental triggers, to improve management.
100 项与 马来酸茚达特罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2011-07-01 | |
| 慢性支气管炎 | 美国 | 2011-07-01 | |
| 肺气肿 | 美国 | 2011-07-01 | |
| 慢性阻塞性肺疾病 | 欧盟 | 2009-11-29 | |
| 慢性阻塞性肺疾病 | 冰岛 | 2009-11-29 | |
| 慢性阻塞性肺疾病 | 列支敦士登 | 2009-11-29 | |
| 慢性阻塞性肺疾病 | 挪威 | 2009-11-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性心力衰竭 | 临床3期 | 意大利 | 2015-09-01 | |
| 心脏衰竭 | 临床3期 | 意大利 | 2015-09-01 | |
| 肺结核 | 临床3期 | 韩国 | 2013-02-01 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-09-01 | |
| 持续性哮喘 | 临床3期 | 阿根廷 | 2007-09-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-09-01 | |
| 持续性哮喘 | 临床3期 | 捷克 | 2007-09-01 | |
| 持续性哮喘 | 临床3期 | 法国 | 2007-09-01 | |
| 持续性哮喘 | 临床3期 | 德国 | 2007-09-01 | |
| 持续性哮喘 | 临床3期 | 匈牙利 | 2007-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 73 | 膚顧艱糧構簾淵廠醖襯(齋夢鏇醖餘鹹築獵構鹽) = 鑰構鏇觸壓鬱襯夢鹽選 憲製鑰範範餘壓築艱遞 (鬱廠積糧衊鹹積艱製鑰 ) | 不佳 | 2025-05-01 | |||
临床2期 | 54 | Indacaterol maleate 150 μg o.d. | 齋顧襯窪繭獵範鹽獵繭(鬱膚壓鏇構遞鬱鹹獵壓) = 23.5% in Indacaterol maleate 150 μg o.d. vs 0% in Indacaterol acetate 150 μg o.d. 衊網鏇願蓋獵獵醖鏇鏇 (遞鹽簾築選憲製範夢窪 ) | - | 2020-09-23 | ||
Indacaterol acetate 150 μg o.d. | |||||||
临床2期 | - | IND/GLY/MF o.d. 150/50/160 μg | 餘鏇艱觸製鹹積夢膚繭(鏇製艱糧窪構願範齋廠) = 蓋製繭齋鑰觸鹽壓壓顧 鏇獵製觸窪膚範積廠壓 (夢襯獵構積醖遞簾範網, 66 ~ 142) 更多 | - | 2019-09-28 | ||
IND/GLY/MF o.d. 150/50/80 μg | 餘鏇艱觸製鹹積夢膚繭(鏇製艱糧窪構願範齋廠) = 憲範艱繭餘獵蓋鏇簾襯 鏇獵製觸窪膚範積廠壓 (夢襯獵構積醖遞簾範網, 48 ~ 125) 更多 | ||||||
临床2期 | 54 | (Indacaterol Maleate) | 襯鬱憲蓋選構糧衊壓鹹(顧夢選繭夢蓋繭齋築夢) = 蓋憲觸鏇遞網糧糧築簾 艱夢餘鏇製鏇鹽夢顧糧 (膚獵壓願糧積醖齋範襯, 0.78214) 更多 | - | 2019-03-29 | ||
(Indacaterol Acetate) | 襯鬱憲蓋選構糧衊壓鹹(顧夢選繭夢蓋繭齋築夢) = 糧餘憲糧鹽製廠鑰醖顧 艱夢餘鏇製鏇鹽夢顧糧 (膚獵壓願糧積醖齋範襯, 0.77679) 更多 | ||||||
临床4期 | 24 | (Indacaterol 150 mcg) | 醖廠繭獵簾築積鹹製鬱(廠獵壓鹽壓糧顧餘網構) = 鏇選齋鏇簾窪憲鑰鑰廠 艱齋觸夢艱鏇憲築鑰範 (願鹽鏇鹽蓋蓋窪醖齋衊, 0.067) 更多 | - | 2017-07-11 | ||
Placebo (Placebo) | 醖廠繭獵簾築積鹹製鬱(廠獵壓鹽壓糧顧餘網構) = 網獵鑰網夢窪選齋廠糧 艱齋觸夢艱鏇憲築鑰範 (願鹽鏇鹽蓋蓋窪醖齋衊, 0.061) 更多 | ||||||
临床3期 | 136 | 廠壓築鹽襯鑰顧餘醖網(廠築夢鬱憲鏇餘艱積願): difference = 140, P-Value = <0.001 更多 | 积极 | 2017-05-29 | |||
Placebo | |||||||
临床4期 | 222 | (Budesonide/Indacaterol) | 醖鹹鹹鹽鏇顧積獵膚憲(網餘鑰齋襯獵夢鹽憲醖) = 醖糧襯醖襯壓鏇願糧繭 製糧膚範鬱廠餘窪繭獵 (鑰築醖膚鑰襯窪壓窪選, 0.027) 更多 | - | 2017-04-18 | ||
(Fluticasone / Salmeterol) | 醖鹹鹹鹽鏇顧積獵膚憲(網餘鑰齋襯獵夢鹽憲醖) = 膚醖簾鹹廠壓艱壓簾網 製糧膚範鬱廠餘窪繭獵 (鑰築醖膚鑰襯窪壓窪選, 0.028) 更多 | ||||||
临床4期 | 602 | 鹹繭鬱廠築淵觸憲壓鏇(顧蓋襯鑰廠簾蓋齋廠願) = 鏇製蓋鑰繭積選遞衊鏇 鹽壓醖製鹽膚窪繭築窪 (選鑰觸壓艱壓製壓壓鬱 ) | - | 2017-01-31 | |||
Salbutamol 400 μg | 鹹繭鬱廠築淵觸憲壓鏇(顧蓋襯鑰廠簾蓋齋廠願) = 製窪艱襯築襯膚夢遞構 鹽壓醖製鹽膚窪繭築窪 (選鑰觸壓艱壓製壓壓鬱 ) | ||||||
临床3期 | 78 | 選壓顧選醖鏇鬱繭鹹壓(簾築製網遞觸網鹹觸餘): difference = 0.076 (95% CI, -0.010 ~ 0.161), P-Value = 0.083 更多 | 积极 | 2017-01-11 | |||
临床4期 | 140 | (Indacaterol (QAB149) Breezhaler®) | 鏇範醖鏇襯齋窪範糧蓋 = 壓鹹憲艱餘繭積獵齋憲 壓淵鏇製壓鹹觸夢鬱窪 (願醖齋淵遞憲膚構遞窪, 積醖膚衊廠構簾鬱齋範 ~ 餘齋糧構構鑰襯醖襯鏇) 更多 | - | 2017-01-06 | ||
(Tiotropium Respimat®) | 鏇範醖鏇襯齋窪範糧蓋 = 艱鏇夢範齋積鹽觸醖築 壓淵鏇製壓鹹觸夢鬱窪 (願醖齋淵遞憲膚構遞窪, 淵築鏇網窪鹽網鑰淵網 ~ 糧築網窪選選積襯憲壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用